InSignia® is a breakthrough technology that differentiates live, active infections from dead organisms or non-viable remnant genetic material [1]. This unique capability addresses a fundamental limitation of molecular diagnostics, where conventional PCR tests can't distinguish between live pathogens that require treatment and dead pathogens that pose no threat [4]. By analyzing the RNA/DNA ratio of detected pathogens, InSignia® provides a superior tool for researching active infections, with future applications informing on pathogen viability for diagnostics, test of cure verification, and clinical trial monitoring.*

Expanding on viability assessment, InSignia® can also monitor marker-agnostic pathogen responses under antibiotic stress. This progressive approach to AST combines the speed of molecular testing with the functional proof of phenotypic testing. Since transcriptional changes occur almost immediately following exposure, InSignia® can use this change for AST without the need for time-consuming and less sensitive culture methods. A recent study has shown that by performing short, temperature-controlled exposures directly on clinical samples, this method can inform on pathogen susceptibility profiles without requiring prior knowledge of specific genetic markers [5].